Top in ID: Paxlovid unlikely contributes to COVID-19 rebound; a roundup of 2023 guidelines

Two separate analyses of studies and trials suggest that COVID-19 rebound is not linked to Paxlovid or other antiviral drugs.
The findings contradict other studies that indicated a higher frequency of COVID-19 rebound among people treated with Paxlovid (nirmatrelvir/ritonavir, Pfizer).
“Rebound is typically described as a recurrence of symptoms after recovery or a new positive viral test after testing negative,” Pragna Patel, MD, MPH, DRM&H, chief medical officer in the Coronavirus and Other Respiratory Viruses division of the CDC’s National Center for Immunization and

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart